Development of Scoring Functions for Antibody Sequence Assessment and Optimization
暂无分享,去创建一个
[1] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[2] Peter M Bowers,et al. An integrated approach to extreme thermostabilization and affinity maturation of an antibody. , 2013, Protein engineering, design & selection : PEDS.
[3] P. Tessier,et al. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. , 2012, Protein engineering, design & selection : PEDS.
[4] N. Lonberg. Human antibodies from transgenic animals , 2005, Nature Biotechnology.
[5] H. Hoogenboom,et al. Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.
[6] G. Gilliland,et al. Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.
[7] Andrew C. R. Martin,et al. Accessing the Kabat antibody sequence database by computer , 1996, Proteins.
[8] T. Boone,et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.
[9] E. Kabat,et al. Sequences of proteins of immunological interest , 1991 .
[10] T. Arakawa,et al. Mechanisms of protein aggregation. , 2009, Current pharmaceutical biotechnology.
[11] D. Altschuh,et al. Covariance analysis of protein families: The case of the variable domains of antibodies , 2000, Proteins.
[12] Andreas Plückthun,et al. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.
[13] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[14] Bernhardt L Trout,et al. Prediction of aggregation prone regions of therapeutic proteins. , 2010, The journal of physical chemistry. B.
[15] Brian M. Murphy,et al. Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.
[16] G. Winter,et al. Making antibodies by phage display technology. , 1994, Annual review of immunology.
[17] A. Plückthun,et al. Transfer of engineered biophysical properties between different antibody formats and expression systems. , 2012, Protein engineering, design & selection : PEDS.
[18] David Baker,et al. Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.
[19] Yvonne Stark,et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties , 2013, mAbs.
[20] Thomas A. Hopf,et al. Protein 3D Structure Computed from Evolutionary Sequence Variation , 2011, PloS one.
[21] Thomas B. Kepler,et al. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody , 2012, Proceedings of the National Academy of Sciences.
[22] Andrew C. R. Martin,et al. Analyzing the "degree of humanness" of antibody sequences. , 2007, Journal of molecular biology.
[23] Anne S De Groot,et al. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.
[24] Gregory A Voth,et al. Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. , 2012, The journal of physical chemistry. B.
[25] François Stricher,et al. The FoldX web server: an online force field , 2005, Nucleic Acids Res..
[26] Steven J Shire,et al. Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.
[27] D. Stock,et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance , 2012, Proceedings of the National Academy of Sciences.
[28] R. Ranganathan,et al. Evolutionarily conserved pathways of energetic connectivity in protein families. , 1999, Science.
[29] P. Tessier,et al. Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.
[30] Stefan M. Larson,et al. Analysis of covariation in an SH3 domain sequence alignment: applications in tertiary contact prediction and the design of compensating hydrophobic core substitutions. , 2000, Journal of molecular biology.
[31] John D. Hunter,et al. Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.
[32] Dmitrij Frishman,et al. Co-evolving residues in membrane proteins , 2007, Bioinform..
[33] D. Altschuh,et al. Functional aspects of co‐variant surface charges in an antibody fragment , 2002, Protein science : a publication of the Protein Society.
[34] William F Weiss,et al. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.
[35] Bernhardt L Trout,et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.
[36] N. Metropolis,et al. Equation of State Calculations by Fast Computing Machines , 1953, Resonance.
[37] Richard W. Aldrich,et al. A perturbation-based method for calculating explicit likelihood of evolutionary co-variance in multiple sequence alignments , 2004, Bioinform..
[38] L. Serrano,et al. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.
[39] Richard W Aldrich,et al. On Evolutionary Conservation of Thermodynamic Coupling in Proteins* , 2004, Journal of Biological Chemistry.